Stem cell therapy in acute myocardial infarction: a review of clinical trials
Stem cell therapy in acute myocardial infarction: a review of clinical trials
复制标题
DOI：
10.1016/j.trsl.2009.06.009
复制
发表时间：
2010-01-01
影响因子：
7.8
通讯作者：
George, Jon C.
中科院分区：
文献类型：
--
作者：
George, Jon C.
干细胞（Stem cells，SC）具有分化为各种组织细胞的能力。虽然在人类中难以证明SC分化为功能性心肌细胞，但在急性心肌梗死（AMI）背景下使用SC的临床试验已经证明了可变的结果。由于多个变量，包括试验设计、细胞类型、细胞递送时间和结果测量的差异，这些试验的解释一直很困难。在此，对AMI中SC治疗的直接注射、间接动员和联合方法亚组的所有临床试验进行了总结，并提供了每组中的显著结果。（翻译研究2010;155：10-19）
Stem cells (SCs) possess the ability to differentiate into cells of various tissues. Although the differentiation of SCs into functional cardiomyocytes has been difficult to demonstrate in humans, clinical trials using SCs in the setting of acute myocardial infarction (AMI) have demonstrated variable results. Interpretation of these trials has been difficult because of multiple variables, which include differences in trial design, cell type, timing of cell delivery, and outcome measurements. Herein, a summary of all clinical trials in subgroups of direct injection, indirect mobilization, and combination approaches of SC therapy in AMI is provided with significant findings in each group. (Translational Research 2010;155:10-19)